Cancer Diagnostics Market Expected To Reach USD 18.4 Billion By 2024
Global Cancer Diagnostics Market, By Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melonoma), By Geography (North America, Europe, Asia-Pacific, Latin America, Rest of the World) – Trends and Forecast to 2024
Global Cancer Diagnostics Market is expected to reach USD 18.4 billion by 2024 from USD 7.6 billion in 2016, at a CAGR of 11.7% in the forecast period 2017 to 2024.The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Request for Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-diagnostics-market
Key factors propelling growth of this market are technological advancements in the diagnostics imaging systems, growing number of cancer patients globally, rapidly aging population, and huge government support for research in cancer diagnostics. However, factors such as the dearth of skilled professionals and high capital investments for imaging systems are restraining the growth of the market.
The market is segmented on the basis of technology and application, and geography.
The global cancer diagnostics market, by technology, is categorized into two main segments—platform based and instrument-based. Platform-based segment is further segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), DNA Microarrays, Flow Cytometry and other technologies. Instrument-based segment is further segmented into Imaging (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), mammography, and ultrasound), and Biopsy.
The global cancer diagnostics market, by application into lung cancer, breast cancer, colorectal cancer, melanoma and other forms of cancer. Breast cancer diagnosis is expected to hold the largest share of this market in 2015, due to very high prevalence in North America also due to very high cost of mammography instruments. While lung cancer is expected to be the fastest growing application in cancer diagnostics market globally during the forecast period 2017 to 2024.
Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Inquiry before Buying Visit @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-diagnostics-market
Some of the major Companies operating in this market are:
• Abbott Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Becton
• Dickinson and Company
• GE Healthcare
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Roche Diagnostics
• Siemens Healthcare
• Philips Healthcare
• C.R. Bard, Inc.
• Hologic, Inc.
Table of Content:
1. INTRODUCTION
2. MARKET SEGMENTATION
3. MARKET OVERVIEW
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
6.1. OVERVIEW
6.2. PLATFORM BASED, BY PRODUCT TYPE
6.3. INSTRUMENT BASED, BY PRODUCT TYPE
7. GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION
9. GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE GLOBAL CANCER DIAGNOSTICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.2. EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10. GLOBAL CANCER DIAGNOSTICS MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL CANCER DIAGNOSTICS MARKET: COMPANY SHARE ANALYSIS
10.2. NORTH AMERICA CANCER DIAGNOSTICS MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE CANCER DIAGNOSTICS MARKET: COMPANY SHARE ANALYSIS
10.4. APAC CANCER DIAGNOSTICS MARKET: COMPANY SHARE ANALYSIS
10.5. MEA CANCER DIAGNOSTICS MARKET: COMPANY SHARE ANALYSIS
10.6. SOUTH AMERICA CANCER DIAGNOSTICS MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.9. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11. GLOBAL CANCER DIAGNOSTICS MARKET, COMPANY PROFILES
11.1. ABBOTT
11.1.1. COMPANY OVERVIEW
11.1.2. FINANCIAL ANALYSIS
11.1.3. PRODUCT MATRIX
11.1.4. RECENT DEVELOPMENTS
11.1.5. DATABRIDGE ANALYSIS
11.2. THERMO FISHER SCIENTIFIC
11.2.1. COMPANY OVERVIEW
11.2.2. FINANCIAL ANALYSIS
11.2.3. PRODUCT MATRIX
11.2.4. RECENT DEVELOPMENTS
11.2.5. DATABRIDGE ANALYSIS
11.3. ILLUMINA, INC.
11.3.1. COMPANY OVERVIEW
11.3.2. FINANCIAL ANALYSIS
11.3.3. PRODUCT MATRIX
11.3.4. RECENT DEVELOPMENTS
11.3.5. DATABRIDGE ANALYSIS
11.4. GE HEALTHCARE
11.4.1. COMPANY OVERVIEW
11.4.2. FINANCIAL ANALYSIS
11.4.4. PRODUCT MATRIX
11.4.4. RECENT DEVELOPMENTS
11.4.5. DATABRIDGE ANALYSIS
11.5. SIEMENS HEALTHCARE GMBH
11.5.1. COMPANY OVERVIEW
11.5.2. FINANCIAL ANALYSIS
11.5.3. PRODUCT MATRIX
11.5.4. RECENT DEVELOPMENTS
11.5.5. DATABRIDGE ANALYSIS
11.6. QIAGEN
11.6.1. COMPANY OVERVIEW
11.6.2. FINANCIAL ANALYSIS
11.6.3. PRODUCT MATRIX
11.6.4. RECENT DEVELOPMENTS
11.6.5. DATABRIDGE ANALYSIS
11.7. AGILENT TECHNOLOGIES
11.7.1. COMPANY OVERVIEW
11.7.2. FINANCIAL ANALYSIS
11.7.3. PRODUCT MATRIX
11.7.4. RECENT DEVELOPMENTS
11.7.5. DATABRIDGE ANALYSIS
11.8. ROCHE DIAGNOSTICS
11.8.1. COMPANY OVERVIEW
11.8.2. FINANCIAL ANALYSIS
11.8.3. PRODUCT MATRIX
11.8.4. RECENT DEVELOPMENTS
11.8.5. DATABRIDGE ANALYSIS
11.9. KONINKLIJKE PHILIPS N.V.
11.9.1. COMPANY OVERVIEW
11.9.2. FINANCIAL ANALYSIS
11.9.3. PRODUCT MATRIX
11.9.4. RECENT DEVELOPMENTS
11.9.5. DATABRIDGE ANALYSIS
11.10. BECTON, DICKINSON & COMPANY
11.10.1. COMPANY OVERVIEW
11.10.2. FINANCIAL ANALYSIS
11.10.3. PRODUCT MATRIX
11.10.4. RECENT DEVELOPMENTS
11.10.5. DATABRIDGE ANALYSIS
11.11. C.R. BARD, INC.
11.11.1. COMPANY OVERVIEW
11.11.2. FINANCIAL ANALYSIS
11.11.3. PRODUCT MATRIX
11.11.4. RECENT DEVELOPMENTS
11.11.5. DATABRIDGE ANALYSIS
11.12. HOLOGIC, INC.
11.12.1. COMPANY OVERVIEW
11.12.2. FINANCIAL ANALYSIS
11.12.3. PRODUCT MATRIX
11.12.4. RECENT DEVELOPMENTS
11.12.5. DATABRIDGE ANALYSIS
Browse Full Report Visit @ http://databridgemarketresearch.com/reports/in-vitro-diagnostics/global-cancer-diagnostics-market/
Related Report
North America Cancer Diagnostics Market – Industry Trends and Forecast to 2024
North America Cancer Diagnostics Market By Product Type, By End User, By Country (U.S., Canada, Mexico) – Industry Trends and Forecast to 2024
Report Access: http://databridgemarketresearch.com/reports/in-vitro-diagnostics/north-america-cancer-diagnostics-market/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog: http://databridgemarketresearch.com/blog/
Follow us on LinkedIn: https://www.linkedin.com/company/data-bridge-market-research